Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
Trial Details
- NCT ID
- NCT06561152
- Phase
- PHASE1 / PHASE2
- Sponsor
- Stanford University
- Status
- RECRUITING
- Cancer Type
- Leukemia
- Interventions
- Tagraxofusp
- Cladribine (CLAD)
- Cytarabine
- Locations (sample)
- Palo Alto, California, United States|37.44188,-122.14302
Key Eligibility Criteria
- Documented diagnosis of relapsed or refractory acute myeloid leukemia (AML) according to World Health Organization (WHO) 2022 criteria
- Expression of CD123 by either flow cytometry or immunohistochemical staining with no minimum threshold for positivity
- Must have received initial therapy with venetoclax in combination with a hypomethylating agent (either azacitidine or decitabine) with no subsequen…
- If mutations in the IDH or FLT3 genes, treatment with IDH or FLT3 inhibitors after initial failure of venetoclax plus HMA is allowed, but not requi…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →